相关实验视频

Updated: Jul 5, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

修改后的Suanmei-Tang对代谢相关脂肪肝疾病的保护作用:网络药理学,代谢学和转录学的综合战略

Chao Wang1, Mei Zhao2, Yuanyuan Yue3

  • 1Traditional Chinese Medicine Department, Qitai Hospital of the Sixth Division, Xinjiang, 831899, People's Republic of China.

Drug design, development and therapy
|November 19, 2024
PubMed
概括

修改后的Suanmei-Tang (MST) 有效地治疗小鼠的代谢相关脂肪肝疾病 (MAFLD). 通过PI3K/AKT/mTOR途径增强自,MST可以改善脂质代谢和肝脏健康.

关键词:
马夫尔德 (MAFLD) 是一个代谢生物组的代谢生物组经过修改的苏安美唐.网络药理学 网络药理学翻译学 翻译学 翻译学 翻译学

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

1.9K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

786

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...